# Q4 FY26 Investor Presentation

*ASX:RCE | FSE:R9Q*

July 2026

# Disclaimer

## DISCLAIMER

This presentation has been prepared by Recce Pharmaceuticals Ltd (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any

potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

## FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

## US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1933 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

# Company Overview



# Recce Pharmaceuticals – Company Overview

*Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones*

**Products address the global healthcare crisis** of antibiotic resistance: working faster than traditional antibiotics and against multidrug resistant bacteria

**Patient dosing has commenced for Phase 3 clinical trial in Indonesia** of lead asset RECCE® 327 Gel for the treatment of Diabetic Foot Infections – interim data readout expected Q3 CY2026 and **commercialisation in 2027**

Recce has signed a non-binding **term sheet with a leading Middle Eastern pharmaceutical company** for a 10-Year exclusive multi-country licensing agreement

Multiple clinical indications and formulations **addressing unmet medical needs**

Agreements with **US Defense Burn Research Program** and **US Army Medical Research Institute** of Infectious Diseases further support Recce's product potential

**RECCE® 327 granted Qualified Infectious Disease Product (QIDP) Designation by U.S. Food and Drug Administration giving 10 years market exclusivity plus fast-track approval.**

**RECCE® 327 added to World Health Organization's List of Antibacterial Products in Clinical Development.**

# Large Addressable Market

*The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems*



| INDONESIA | MENA | GLOBAL |
|---|---|---|
| **>20 million** | **>84 million** | **>589 million** |
| adults in Indonesia with diabetes[3] | adults in MENA region with diabetes[4] | adults globally with diabetes[5] |

- For adults with diabetes, **approximately one in three adults will develop a diabetic foot ulcer** in their lifetime[6]
- In Indonesia, DFIs are severe in **67.1% of hospitalised cases** and **result in amputation in 46.9% of patients**[7]

*Source: (1) Grand View Research, Diabetic Foot Ulcer Treatment Market Size, 2025 (2) Grand View Research, Anti-Infective Agents Market Size, 2023 (3) Diabetes Atlas, International Diabetes Federation (IDF) and Prof EM Yunir, Faculty of Medicines, University of Indonesia. (4) https://diabetesatlas.org/data-by-location/region/middle-east-and-north-africa/ (5) https://idf.org/about-diabetes/diabetes-facts-figures/ (6) The current burden of diabetic foot disease – PMC (7) https://doi.org/10.1016/j.heliyon.2024.e41263*

# Key highlights for the quarter ended 30 June 2026

*A transformational quarter delivering regulatory, clinical and commercial milestones that further de-risk Recce's global development strategy*

## Clinical Update

**Australian DFI study advanced to a pivotal Phase 3 registrational trial.**

Patient eligibility expanded to include Moderate DFI, significantly increasing recruitment potential.

Trial design strengthened through additional ulcer-level endpoint analysis.

## Regulatory Progress

**Indonesian BPOM completed a comprehensive inspection with no findings or required changes.**

Australian HREC approved protocol amendments supporting an accelerated global registration strategy.

Two registrational Phase 3 studies now operating concurrently.

## Commercialisation

**Signed non-binding licensing term sheet with a leading Middle Eastern pharmaceutical company.**

Proposed agreement includes upfront payments, milestones, product revenue share and royalties.

Commercial negotiations progressing toward a definitive agreement.

## Global Expansion

**Dual Phase 3 strategy now supports future registrations across Australia, Indonesia, ASEAN, MENA and the United States.**

MENA licensing opportunity covers 12 countries with access to one of the world's highest diabetes burden regions.

Recce continues building a global commercial platform.

# Registrational Phase 3 Clinical Trial - Australia

***Randomised, Active Comparator Study of R327 Topical Gel for the Treatment of Diabetic Foot Infections***

## Timeline

| 2026 | 2027 | 2028 |
|---|---|---|

### R327 Topical

**DFI**
Australia/USA

Additional Registrational Clinical Trials and Data for AUS/US Approval

**Phase 3 Interim Data Readout**

**R327G Registered in Australia/US**

## Study Overview

**TGA and US FDA regulatory standards**

**Expanded Patient Population**

Protocol amendment adds moderate DFI. Mild and Moderate DFI together represent 80% of DFI presentations[1].

**Endpoints**

**Primary Endpoint:** Assess the **clinical response** of the DFI according to the Lipsky Scale.
**Secondary Endpoints:** DFI total **wound score and safety** of R327G.



1 Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clinical Infectious Diseases. 2007;44(4):562–565.

# Routine Regulatory Inspection of Indonesian Sites

- **Comprehensive regulatory inspection successfully completed for Phase 3 clinical trial site for the treatment of DFIs**
  - Inspection formed part of BPOM's standard regulatory oversight of clinical studies and included a comprehensive review of trial conduct, site processes, data integrity, and compliance with applicable Good Clinical Practice (GCP) standards.

- **Indonesian National Agency of Drug and Food Control (Badan POM) has not requested any changes to the ongoing clinical trial**
  - The inspection was completed with no findings noted that prevent the study from continuing.
  - The outcome reflects the high quality of the Recce's clinical operations in Indonesia and adherence to regulatory requirements.

- **Phase 3 clinical trial patient dosing continues across five sites with interim data analysis to be conducted at 155 patients completed**
  - BPOM inspection represents a critical de-risking milestone for Recce's registrational Phase 3 clinical trial in Indonesia and supports the pathway toward regulatory approval and commercialisation in Indonesia followed by other ASEAN countries.

**Indonesian Minister of Health, Mr. Budi Sadikin:**

*"The global health challenge of antimicrobial resistance is a pressing issue on the world stage. Indonesia welcomes collaborative initiatives and supports efforts to combat antimicrobial resistance, including the development of innovative therapeutics for infectious diseases."*

# Program Pipeline* driven by 1st approval in Diabetic Foot Infections




recce.com.au

*The information and forecasts presented reflect management's current expectations as at the date of this presentation. These statements involve assumptions, including the availability of appropriate funding, and are subject to known and unknown risks and uncertainties. Actual outcomes may differ from those expressed or implied and the Company reserves the right to revise its plans, projections, and strategic priorities as circumstances change.

# Recce Global Growth Strategy

*Indonesian regulatory approval serves as a foundation for a cascading global approval strategy across multiple regions*

**Global Approvals**


| | Gel | IV | Aerosol |
|---|---|---|---|
| **New Products and New Indications** | DFI Gel<br>ABSSSI Gel<br>Burn Gel | IV cUTI<br>IV Sepsis<br>IV Single Dose UTI | Aerosol HAP / VAP<br>Aerosol non-TB Mycobacteria<br>Intranasal Sinusitis |

# Middle Eastern Pharmaceutical Company Term Sheet

*Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive multi-country licensing agreement for the licensing of R327G through the MENA region*

## Term Sheet Highlights

| | |
|---|---|
| **Unlocks MENA Diabetes Market** | • The MENA region has a diabetes prevalence of 17.6% with over 84 million people living with diabetes – in Saudi Arabia, **23.1% of the adult population have been diagnosed with diabetes**<br>• The non-binding Term Sheet coverage is across the KSA, GCC countries (UAE, Kuwait, Oman, Bahrain, Qatar), Iraq, Egypt, Algeria and Morocco |
| **Validation of Premium Pricing** | • Non-binding Term Sheet stipulates a **proposed selling price of USD $1,500 per treatment** or a price mutually agreed with the KSA regulatory authority<br>• Recce expected to receive **30% of the Net Selling Price** with an additional 6% annual royalty on net sales >USD$50 million/year |
| **Data Harmonisation from Indonesia** | • Successful data read outs in Indonesia together with subsequent regulatory approval would support commercialisation in Indonesia and may support similar regulatory approval and commercialisation in other ASEAN markets.<br>• Pending positive Phase 3 clinical trial results from the ongoing Indonesian trial, no additional clinical trials are expected to be required to support a marketing authorisation application in Saudi Arabia |
| **Commercial Partnership with Leading Company** | • The partner is recognised as one of **the leading pharmaceutical companies in the MENA region**<br>• With a strong sales portfolio of products across dermatology, endocrinology and infectious diseases and established market access throughout the region, the partner is well positioned to accelerate the adoption and distribution of R327G |

***Non-binding term sheet is a positive step towards the potential commercialisation of R327G across one of the world's most significant diabetes markets***

# Intellectual Property



# Robust Worldwide Intellectual Property Portfolio

*Recce's patent portfolio contains over 40 patents and patent applications in the world's major markets.*

| Filed | Patent Family 1 | Expiry | Patent Family 2 | Expiry | Patent Family 3 | Expiry | Patent Family 4 | Expiry |
|---|---|---|---|---|---|---|---|---|
| Australia | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | ✓ | 2041 |
| USA | ✓ | 2029 | ✓ | 2037 | ✓ | 2037 | Pending | |
| Europe | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | Pending | |
| Germany | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | | |
| Spain | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | | |
| France | ✓ | 2029 | ✓ | 2037 | ✓ | 2037 | | |
| UK | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | | |
| Italy | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | | |
| Sweden | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | | |
| Japan | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | ✓ | 2041 |
| China | ✓ | 2028 | ✓ | 2037 | ✓ | 2037 | ✓ | 2041 |
| HK | Pending | 2028 | Pending | 2037 | ✓ | 2037 | ✓ | 2041 |
| Israel | | | | | | | ✓ | 2041 |
| Canada | | | | | | | ✓ | 2041 |
| Brazil | | | | | | | ✓ | 2041 |
| Vietnam | | | | | | | ✓ | 2041 |

**Family 1** group relates to the Company's Unique and Highly Economical Manufacturing Process and use of the Polymer in Treatment of Diseases.

**Family 2** relates to the Method of Manufacture, Administration and Application to Treat a Broad Range of Common Human Infections.

**Family 3** relates to a Method of Treatment of a Broad Range of Viral Infections, particularly Parenteral Viral Infection.

**Family 4** relates to Process for Preparation of Biologically Active Copolymer, other Patent Cooperation Treaty countries pending/granted.

# Share Purchase Plan Now Open and Use of Funds

| Event | Date |
|---|---|
| SPP Record Date | 7:00pm (AEST), Thursday, 25 June 2026 |
| SPP Offer Booklet made available to eligible shareholders and SPP Offer open date | Monday, 6 July 2026 |
| *Revised* SPP offer closing date | 5:00pm (AEST) Friday, 24 July 2026 |
| *Revised* Last day to announce results of SPP | Friday, 31 July 2026 |
| *Revised* Allotment and issue of new shares under the SPP | Friday, 31 July 2026 |
| *Revised* Commencement of trading of new shares under the SPP | Monday, 3 August 2026 |
| General Meeting (GM) | On or about Monday, 31 August 2026 |
| Lodgement of Prospectus with ASIC and ASX in relation to Attaching Options and Piggyback Options | On or about Wednesday, 2 September 2026 |

**Use of Funds and Available Liquidity**

Funds raised under the Placement and SPP will be used for the following activities:

- **A$3.2 million** – Strengthen the balance sheet for commercial licensing with leading Middle Eastern Pharmaceutical Company including initiatives to support the commercial agreement
- **A$2.0 million** – Clinical trials (significant, unmet medical needs) including:
  - Completion of Phase 3 DFI Registrational Topical Clinical Trial in Indonesia
  - Phase 3 DFI Registrational Topical Clinical Trial in Australia (for US FDA)
  - Continuance of US Department of War Burn Wound Program
- **A$2.0 million** – Activities enabling Investigational New Drug application to FDA & the Indonesia FDA (BPOM)
- **A$0.8 million** – General working capital (operational costs delivering above) and Offer costs

***Under the SPP, Eligible Shareholders will have the opportunity to purchase Shares up to the value of $30,000 at an issue price of A$0.40 per Share, irrespective of the size of their shareholding in Recce, without incurring brokerage or transaction costs.***

***Eligible Shareholders are registered holders of shares in the Company as at 7:00pm Australian Eastern Standard Time (AEST) on 25 June 2026 (Record Date) and whose registered address on the Company's share register is in Australia, New Zealand or in the United States (provided that such US shareholders are Accredited Investors).***

# Company Financials

*Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives*

| Capital Structure – July 2026 | |
|---|---|
| ASX & FSE Code | RCE, R9Q |
| **Share Price** | **AUD $0.385** |
| 3-Month Average Daily Volume | 160.98k |
| **Shares on Issue** | **289.18 million** |
| Unlisted Options (Avg $1.087) | 24.17 million |
| **Market Capitalisation** | **AUD $115.3 million** |
| Top 20 Shareholders | 57% |

RCE Share Price and Volume Chart – 12 Months (price shown in AUD)




## *Recce Pro-forma Cash Position*

The Company expects the **receipt of further non-dilutive funds and capital raise proceeds**, which **extends Recce's pro-forma cash position of AUD ~$33.1 million*** (previously $29.5 million).

**Breakdown of cash position:**

- Income tax refund from ATO of A$3.6m (recently announced)
- Estimated R&D rebate of A$7.5 million from the ATO in 2026
- Non-dilutive capital anticipated in 2026 through R&D advance ($A10 million)
- Pro-forma cash position of A$33.1 million post capital raising

**Includes proceeds from Capital Raise (before offer costs) and if debt component is drawn (subject to certain time limitations and the satisfaction of certain conditions)*

# Summary

*Recce is approaching a number of near term significant value creating opportunities with commercialisation*

Novel, Synthetic, Broad-Spectrum, Rapid-Acting, Anti-Infectives: **demonstrated against >500 clinical isolates** including all resistant species; **no signs of resistance to R327**

**Approaching pivotal clinical and commercial inflection point** with interim data read out for Indonesian Phase 3 registrational clinical trial expected commercialisation 2027

Upon completion of Phase 3 registrational clinical trial, enables Recce to **commence commercialisation across ASEAN and MENA region**

**Non-binding term sheet with leading Middle Eastern pharmaceutical company** to support commercial sales and distribution capability through MENA region

**Development of a first new class of antibiotic in over 40 years,** recognised by the World Health Organization, with accelerated de-risking via registrational Phase 3 trials in Indonesia and Australia

# Thank you